Bio-Works has confirmed a new order for a customized, prepacked solution worth SEK 0.8 million to be used in a viral vector manufacturing process. The initial order is for process validation runs, and the potential annual revenue from the project is estimated to be between SEK 3-12 million. The customer is an American contract manufacturer of gene therapy products.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.94 SEK | -.--% | +1.38% | -58.59% |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-58.59% | 10.43M | |
-3.72% | 184B | |
-2.60% | 107B | |
-3.79% | 67.78B | |
+2.66% | 50.66B | |
+16.39% | 47.64B | |
+4.60% | 41.12B | |
+1.38% | 26.3B | |
+1.52% | 26.04B | |
-1.17% | 24.71B |
- Stock Market
- Equities
- BIOWKS Stock
- News Bio-Works Technologies AB
- Bio-Works Secures SEK 0.8 Million Order for Gene Therapy Manufacturing